History of Formation

Affitech was established in 1997 by a group of Norwegian and German scientists on the basis of the acquisition of the worldwide exclusive rights from German Cancer Center, Heidelberg, Germany of “Breitling “ IP which covered phagemid display of human antibodies.

In May 2009, Affitech AS was combined with Pharmexa A/S to form Affitech A/S resulting in the company now being listed on the Nasdaq OMX Copenhagen exchange.

News

August 26, 2010
June 8, 2010
Affitech held an Extraordinary General Meeting, on 30th June, 2010 at 11.00 am at Dronninggårds Allé 136, 2840 Holte...